Abstract: According to the present invention, there is provided a method for treating chronic lymphocytic leukemia (CLL) in a mammal. Beta-carotene is administered to the mammal in CLL therapeutically effective amounts. The invention also contemplates a method for treating T-cell chronic lymphocytic leukemia (T-CLL). T-CLL therapeutically effective amounts of beta-carotene are administered. In further embodiment, a method for lowering or maintaining the level of white blood cells in a mammal having chronic lymphocytic leukemia is provided. White blood cell therapeutically effective amounts of beta-carotene are administered to the mammal.

Abstract: A process for the continusous preparation of Beta-carotene together with an emulsifier by briefly heating Beta-carotene together with an emulsifier to give a homogeneous solution, rapidly cooling the latter to below 100.degree. C. by adding water, and subsequently adjusting to the required final concentration of Beta-carotene, comprises pumping a suspension, which has been preheated from 20.degree. to 80.degree. C., of 1 to 40% by weight of Beta-carotene in an emulsifier through a heating coil located in a heat transfer oil, where the solubilization mixture is at from 120.degree. to 180.degree. C. and the residence time is from 10 to 300 seconds, and subjecting the homogenous solution to turbulent mixing in a mixing chamber with an amount of water at from 10.degree. to 80.degree. C. to result in a solubilizate which contains from 0.5 to 6% by weight of Beta-carotene and is, if necessary, diluted to the required final concentration.

Abstract: Derivatives of long-chain fatty alcohols, and methods of obtaining them, are provided, as well as pharmaceutical compositions containing derivatives and their uses, in particular in treating or preventing neuro-degenerative illnesses, conditions linked to skin ageing, the phenomena of thrombosis and atherosclerosis, and immune deficiencies.

Abstract: The present invention relates to novel potassium channel agonists which are useful in activating the calcium activated Maxi-K potassium channel in mammalian neuronal and smooth muscle tissue. The claimed compounds are of the general formula: ##STR1## In addition, a novel microbiological process for producing the claimed compounds is described.

Abstract: Disclosed are stable liquid products as consisting essentially ofat least one finely dispersed physiologically tolerated fat-soluble substance as disperse phase;glycerol or glycerol mixed with water as continuous phase; andesters of ascorbic acid with long-chain fatty acids as an emulsifier and stabilizer.

Abstract: A composition of an effective amount of (a) .gamma.-linolenic acid and/or dihomo-.gamma.-linolenic acid, optionally in association with linoleic and if desired other fat acids, said acids being used if desired as physiologically functional derivatives thereof, in conjunction with (b) an effective amount of one or more of natural or synthetic carotenoids or retinoids having, or giving rise in the body to compounds having, Vitamin A activity when used in therapy of a condition in which enhancement of 1-series PG production, or more broadly influence of the 1-series/2-series PG balance in the body in favor of 1-series PGs is required.

Abstract: A method and composition for effective removal of a tick from a human or animal host.

Abstract: A composition for preventing or limiting the attack and infestation of trees by pine bark beetles, by inhibiting the response of the beetles to their aggregation pheromones. The composition comprises a green leaf volatile selected form six carbon alcohols, aldehydes, their derivatives such as acetates, and mixtures thereof. The green leaf volatile may be employed alone or in combination with an additional, known inhibitor of the pheromone response of the beetle.

Abstract: The present invention provides a method of medical treatment for systemic disorders and oral pharyngeal conditions in a mammal. In this method, a pharmacologically effective amount for treatment of the disorder or condition of a trioxolane or a diperoxide of an unsaturated hydrocarbon, such as a terpene or non-terpene, is applied to the mammal. The invention also provides pharmaceutical compositions for use in these methods.

Abstract: A method for preventing acetaminophen toxicity in a mammal is provided. An acetaminophen toxicity inhibiting amount of beta-carotene is administered before, simultaneously with, after, or any combination thereof, administering acetaminophen to the mammal. Methods for reducing acetaminophen toxicity in a mammal in need of such treatment and for increasing the maximum amount of acetaminophen that can be administered to a mammal without the mammal exhibiting acetaminophen toxicity are also provided. Acetaminophen toxicity reducing amounts and acetaminophen toxicity preventing amounts, respectively, are administered. In another embodiment, a non-steroidal analgesic and anti-inflammatory composition of acetaminophen and an acetaminophen toxicity preventing amount of beta-carotene is provided.

Abstract: The present invention relates to the use of posttranslational modification inhibitors, such as isoprenylation inhibitors, to inhibit activation of phagocyte NADPH oxidase and respiratory burst. Therapeutic compositions containing various inhibitors, and methods of using same, are also disclosed.

Abstract: A process for producing a stable, bactericidal and fungicidal composition which consists essentially of bubbling air or oxygen into limonene, to produce an oxidized limonene having a rapid bactericidal activity as evidenced by the capability of killing substantially all of the bacteria in a suitable culture medium inoculated with 10.sup.6 colony forming units of Staphylococcus aureus ATCC 25923 per ml. of said broth, containing not more than 0.06 ml of said oxidized limonene per ml. of said broth and incubated at 37.degree. C. in air for 60 minutes.

Abstract: The present invention relates to an intravascular embolizing agent containing an angiogenesis-inhibiting substance and an intravascular embolizing substance. The agent strengthens the antitumor effect of an angiogenesis-inhibiting substance and serves to reduce the dose and undesirable side effects. And use of the agent in concert with an anti-neoplastic agent brings about further strong and long-lasting antitumor effects.

Abstract: Described are isomeric mixtures of bisabolene prepared by dehydrating nerolidol using citric acid or phosphoric acid and then distilling the resulting product at particular temperature ranges and particular pressure ranges in order to prepare a composition of matter useful for augmenting or enhancing natural, dry, floral, opoponax aromas with floral, freesia, fruity, citrus, bergamot, mango and opoponax topnotes in perfume compositions, colognes and perfumed articles (e.g., solid or liquid anionic, cationic, nonionic or zwitterionic detergents, fabric softener composiitions, drier-added fabrics softener articles, cosmetic powders and the like; and useful for repelling specific species of insects, namely, house flies Musca domestica L. (Diptera Muscidae)) and the species of mosquitoes, Aedes aegypti.

Abstract: A transdermal therapeutic formulation comprising d-limonene and at least one pharmaceutically active substance wherein the content of the d-limonene is in the range from 0.1 to 2 weight percent, based on the total amount of the formulation. The transdermal therapeutic formulation has an excellent percutaneous absorption, is safe and is capable of delivering desired pharmaceutically active substances to a desired location of treatment or to the entire body of a patient through the circulatory system and is thus effective for curing various diseases.

Abstract: A process for producing a stable, bactericidal and fungicidal composition which consists essentially of bubbling air or oxygen into limonene, to produce an oxidized limonene having a rapid bactericidal activity as evidenced by the capability of killing at least 99.99% of the bacteria in a suitable culture medium inoculated with 10.sup.6 colony forming units of Staphylococcus aureus ATCC 25923 per ml.

Abstract: A method is provided for sterilizing anthers of plants, such as Gramineae or Helianthus annuus (sunflower) by applying a sterilizing agent to the plants at the fifth and/or sixth stage of organogenesis, chosen from among terpenoid compounds of the methylcyclohexene series.

Abstract: A therapeutic and prophylactic agent for peptic ulcers comprising as an effective ingredient a cyclohexane derivative represented by general formula (I): ##STR1## wherein A represents a group shown by formula, >CH.sub.2, ##STR2## wherein X represents ethynylene, vinylene or ethylene, Y represents oxo or a hydroxy group; R.sup.1, R.sup.3, R.sup.4 and R.sup.5 each represents a hydrogen atom or alkyl; R.sup.2 represents a hydrogen atom, alkyl or a group shown by --OR.sup.8 ;R.sup.6 represents a hydrogen atom, oxo or a group shown by --OR.sup.8 ; and R.sup.7 represents a hydrogen atom or a group shown by --OR.sup.8, wherein R.sup.8 represents a hydrogen atom or an organic residue.

Abstract: Novel external medications comprise, as essential components, the following three components (A) to (C):(A) an .alpha.-monoglyceryl ether represented by the following formula (I): ##STR1## wherein R means an alkyl or alkenyl group having 10 - 24 carbon atoms; (B) a physiologically active material; and(C) an oily material.The external medications have extremely high skin occlusive properties and significantly-improved absorptivity of phosiologically active materials. Therefore, a smaller amount of the medications compared with the conventional ones can give sufficient pharmacological effects and thus side effects can be reduced. The external medications may contain physiologically active materials such as drugs, growth hormones and the like, which are expected to show pharmacological effects upon their percutaneous absorption.

Abstract: A composition is provided for suppressing formation of fat in animals comprising a blend of animal feed and polyterpenes of formula (C.sub.10 H.sub.16).sub.n, where n is an integer from 2 to 4. The polyterpenes may be generated in situ by the reaction of citrus essential oils with pharmaceutically acceptable acid or by direct synthesis. A method for suppressing body fat in both animals and humans is also disclosed comprising feeding or ingesting, respectively, polyterpenes prepared either by direct polymerization of neat terpenes or by the aforementioned in situ reaction.

Abstract: A gallstone dissolver comprises the following active ingredients (A) and (B);(A) a compound selected from the group consisting of fatty acid monoglycerides of C-6 to C-12, fatty acid diglycerides in liquid phase at 30.degree. C., fatty acid triglycerides in liquid phase at 30.degree. C., and fatty acids in liquid phase at 30.degree. C., and(B) a monoterpene.The coexistence of the fatty acid and monoterpene in the gallstone dissolver accelerates the sulubility and dissolving velocity of cholesterol gallstones.A nonionic surfactant such as a polyoxyethylene sorbitan fatty acid ester, glycerin fatty acid ester, etc. may also be added to the above dissolver to further improve the performance of the dissolver.

Abstract: Method and pharmaceutical composition for topically treating skin inflammatory disorders by administering to the inflamed area a therapeutically effective amount of candelilla wax or a saturated hydrocarbon fraction from candelilla wax comprising a mixture of saturated straight chain C.sub.29 -C.sub.33 hydrocarbons, predominantly C.sub.31 hydrocarbon.

Abstract: A composition is provided for suppressing formation of fat in animals comprising a blend of animal feed and polyterpenes of formula (C.sub.10 H.sub.16).sub.n, where n is an inter from 2 to 4. The polyterpenes may be generated in situ by the reaction of citrus essential oils with pharmaceutically acceptable acid or by direct synthesis. A method for suppressing body fat in both animals and humans is also disclosed comprising feeding or ingesting, respectively, polyterpenes prepared either by direct polymerization of neat terpenes or by the aforementioned in situ reaction.